The Biological Technologies Office is holding a Proposers Day to provide information on the structure and objectives of the Panacea program. Panacea aims to integrate systems pharmacology and advanced medicinal chemistry approaches to expand the human drug target space for therapeutic interventions in the areas of acute management of pain and inflammation and the improvement of physiological endurance under oxygen-limited conditions or environments. Panacea will support the development and proof-of-concept demonstration of a new integrated platform for the rapid prediction, synthesis, and validation of pharmacological interventions.
Advance registration is required to participate in the Proposers Day. Additional details, including registration instructions, are available at https://go.usa.gov/xP6hD. Please address administrative questions to DARPA-SNfirstname.lastname@example.org, and refer to the Panacea Proposers Day (DARPA-SN-19-12) in all correspondence.
DARPA hosts Proposers Days to provide potential performers with information on whether and how they might respond to the Government’s research and development solicitations and to increase efficiency in proposal preparation and evaluation. Therefore, the Panacea Proposers Day is open only to registered potential applicants, and not to the media or general public.
DARPA anticipates sharing additional program details in a forthcoming Broad Agency Announcement to be posted to the Federal Business Opportunities website.
You are now leaving the DARPA.mil website that is under the control and
management of DARPA. The appearance of hyperlinks does not constitute
endorsement by DARPA of non-U.S. Government sites or the information,
products, or services contained therein. Although DARPA may or may not
use these sites as additional distribution channels for Department of
Defense information, it does not exercise editorial control over all of
the information that you may find at these locations. Such links are
provided consistent with the stated purpose of this website.
After reading this message, click to continue